Preclinical models have been used to test efficacy of mTOR and JAK inhibitors in CRLF2-rearranged and JAK2-mutated high-risk precursor B-cell ALL (Maude et al. 2011).
Suggested Citation: Brown, V., S. Borinstein, D. Friedman. 2018. JAK2. My Cancer Genome https://www.mycancergenome.org/content/disease/myeloproliferative-neoplasms/jak2/?tab=0 (Updated April 3).
Last Updated: April 3, 2018